Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
|
|
Stoke Therapeutics, Inc. (STOK)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
8-K
| Quarterly results|
Docs:
|
"Stoke Therapeutics, Inc. Consolidated balance sheets June 30, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 192,060 $ 113,556 Marketable securities 39,387 116,039 Prepaid expenses 10,950 10,932 Other current assets 3,699 2,955 Interest receivable 136 588 Total current assets $ 246,232 $ 244,070 Restricted cash 569 569 Operating lease right-of-use assets 3,646 4,753 Property and equipment, net 6,472 6,675 Total assets $ 256,919 $ 256,067 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 1,556 $ 766 Accrued and other current liabilities 12,222 15,748 Deferred revenue - current portion 8,059 14,880 Total current liabilities $ 21,837 $ 31,394 Deferred revenue - net of current portion 43,258 36,856 Other long term liabilities 1,629 2,968 T..." |
|
| 07/25/2023 |
8-K
| Quarterly results |
| 07/06/2023 |
4
| Ticho Barry (Chief Medical Officer) has filed a Form 4 on Stoke Therapeutics, Inc.|
Txns:
| Sold 15,000 shares
@ $10.5982, valued at
$159k
|
|
| 06/15/2023 |
4
| TZIANABOS ARTHUR (Director) has filed a Form 4 on Stoke Therapeutics, Inc.|
Txns:
| Granted 19,441 options to buy
@ $12.46, valued at
$242.2k
|
|
| 06/15/2023 |
4
| Smith Julie (Director) has filed a Form 4 on Stoke Therapeutics, Inc.|
Txns:
| Granted 19,441 options to buy
@ $12.46, valued at
$242.2k
|
|
| 06/15/2023 |
4
| Menzel Garry E (Director) has filed a Form 4 on Stoke Therapeutics, Inc.|
Txns:
| Granted 19,441 options to buy
@ $12.46, valued at
$242.2k
|
|
| 06/15/2023 |
4
| LEVIN ARTHUR A (Director) has filed a Form 4 on Stoke Therapeutics, Inc.|
Txns:
| Granted 19,441 options to buy
@ $12.46, valued at
$242.2k
|
|
| 06/15/2023 |
4
| Krainer Adrian R. (Director) has filed a Form 4 on Stoke Therapeutics, Inc.|
Txns:
| Granted 19,441 options to buy
@ $12.46, valued at
$242.2k
|
|
| 06/15/2023 |
4
| Harrison Seth Loring (Director) has filed a Form 4 on Stoke Therapeutics, Inc.|
Txns:
| Granted 19,441 options to buy
@ $12.46, valued at
$242.2k
|
|
| 06/15/2023 |
4
| Burstein Jennifer (Director) has filed a Form 4 on Stoke Therapeutics, Inc.|
Txns:
| Granted 19,441 options to buy
@ $12.46, valued at
$242.2k
|
|
| 06/05/2023 |
4
| Ticho Barry (Chief Medical Officer) has filed a Form 4 on Stoke Therapeutics, Inc.|
Txns:
| Sold 15,000 shares
@ $11.1309, valued at
$167k
|
|
| 05/24/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/08/2023 |
4
| Ticho Barry (Chief Medical Officer) has filed a Form 4 on Stoke Therapeutics, Inc.|
Txns:
| Sold 653 shares
@ $10, valued at
$6.5k
|
|
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 05/03/2023 |
4
| Ticho Barry (Chief Medical Officer) has filed a Form 4 on Stoke Therapeutics, Inc.|
Txns:
| Sold 24,967 shares
@ $10.0039, valued at
$249.8k
Sold 5,513 shares
@ $10.0007, valued at
$55.1k
Sold 24,697 shares
@ $10.1375, valued at
$250.4k
|
|
| 05/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/17/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/13/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/22/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/17/2023 |
4
| Allan Jonathan (General Counsel & Corp Sec) has filed a Form 4 on Stoke Therapeutics, Inc.|
Txns:
| Granted 44,800 options to buy
@ $9.15, valued at
$409.9k
Granted 29,900 restricted stock units
@ $0 |
|
| 03/17/2023 |
4
| Tulipano Stephen J (CFO) has filed a Form 4 on Stoke Therapeutics, Inc.|
Txns:
| Granted 78,600 options to buy
@ $9.15, valued at
$719.2k
Granted 52,400 restricted stock units
@ $0 |
|
| 03/17/2023 |
4
| Ticho Barry (Chief Medical Officer) has filed a Form 4 on Stoke Therapeutics, Inc.|
Txns:
| Granted 78,600 options to buy
@ $9.15, valued at
$719.2k
Granted 52,400 options to buy
@ $0 |
|
| 03/17/2023 |
4
| Nash Huw M. (COO & CBO) has filed a Form 4 on Stoke Therapeutics, Inc.|
Txns:
| Granted 78,600 options to buy
@ $9.15, valued at
$719.2k
Granted 52,400 restricted stock units
@ $0 |
|
| 03/17/2023 |
4
| Kaye Edward M. MD (CEO) has filed a Form 4 on Stoke Therapeutics, Inc.|
Txns:
| Granted 213,000 options to buy
@ $9.15, valued at
$1.9M
Granted 142,000 restricted stock units
@ $0 |
|
| 03/17/2023 |
3
| Allan Jonathan (General Counsel & Corp Sec) has filed a Form 3 on Stoke Therapeutics, Inc. |
| 03/15/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 03/06/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/06/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
|
|
|